Status:
COMPLETED
Sugammadex on Remifentanil Ce for Preventing Emergence Cough in Female
Lead Sponsor:
Ajou University School of Medicine
Conditions:
Gallbladder Diseases
Eligibility:
FEMALE
19-60 years
Phase:
NA
Brief Summary
The purpose of this study is to investigate the optimal Ce of remifentanil for preventing emergence cough following extubation during general anesthesia in female who are reversed with sugammadex or n...
Detailed Description
Remifentanil is a potent ultrashort-acting opioid, with rapid onset and offset of drug effect. It allows rapid anesthetic emergence even after a prolonged infusion, and decreases the at-risk time duri...
Eligibility Criteria
Inclusion
- Laparoscopic cholecystectomy under general anesthesia
Exclusion
- BMI \> 30 kg/m2, respiratory infection, uncontrolled hypertension
Key Trial Info
Start Date :
December 2 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 6 2021
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04407078
Start Date
December 2 2019
End Date
January 6 2021
Last Update
January 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Anesthesiology and Pain Medicine, Ajou University School of Medicine
Suwon, Gyeonggido, South Korea, 16499